Findings of a phase II trial investigating the antiangiogenic agent pazopanib in patients with platinum-refractory advanced-stage ovarian cancer reveal that treatment with pazopanib plus paclitaxel resulted in significantly longer median progression-free survival than paclitaxel therapy alone (6.4 months versus 3.5 months; P = 0.00042). Pazopanib treatment, although well-tolerated, resulted in more severe adverse events than paclitaxel alone. These findings indicate a need to test this agent in phase III trials.